Select therapeutic use:

Head and neck cancer:

Indications for HYDREA:

Adjunct with irradiation therapy in locally advanced squamous cell carcinomas of the head and neck, excluding the lip.

Adult:

Base dose on ideal or actual weight, whichever is less. Individualize. Initially 15mg/kg/day. Renal impairment (CrCl <60mL/min or ESRD): initially 7.5mg/kg/day; give dose following dialysis (monitor). Dose modifications: see full labeling.

Children:

Not established.

Boxed Warning:

Myelosuppression. Malignancies.

Warnings/Precautions:

Risk of severe myelosuppression; reduce dose or discontinue if necessary. Monitor blood counts at baseline and at least once a week during therapy. Correct severe anemia before starting. Markedly depressed bone marrow function: do not initiate. Monitor for malignancies. Avoid sun exposure. Previous irradiation therapy (monitor for skin erythema) or chemotherapy. Macrocytosis may mask folic acid deficiency; prophylactic folic acid is recommended. Pulmonary toxicity. Myeloproliferative disorders; discontinue if cutaneous vasculitic ulcerations occur. Renal or hepatic impairment. Elderly. Embryo-fetal toxicity. Pregnancy; avoid. Exclude pregnancy prior to initiating; use effective contraception during and for ≥6 months (females) or ≥1 year (males) after therapy. Nursing mothers: not recommended.

Pharmacologic Class:

Antimetabolite.

Interactions:

Avoid concomitant didanosine, with or without stavudine, or other antiretrovirals (may cause pancreatitis [monitor], fatal hepatotoxicity, peripheral neuropathy). Avoid live vaccines. Increased risk of vasculitic toxicities with interferon therapy. May cause falsely elevated results in urea, uric acid, and lactic acid assays.

Adverse Reactions:

Leukopenia, thrombocytopenia, anemia, GI upset, anorexia; secondary malignancies, macrocytosis, interstitial lung disease.

Note:

Wear disposable gloves when handling caps or bottle.

How Supplied:

Caps—100

Pricing for HYDREA

500mg capsule (Qty: 60)
Appx. price $28
GoodRx

Leukemias, lymphomas, and other hematologic cancers:

Indications for HYDREA:

Resistant chronic myeloid leukemia.

Adult:

Base dose on ideal or actual weight, whichever is less. Individualize. Initially 15mg/kg/day. Renal impairment (CrCl <60mL/min or ESRD): initially 7.5mg/kg/day; give dose following dialysis (monitor). Dose modifications: see full labeling.

Children:

Not established.

Boxed Warning:

Myelosuppression. Malignancies.

Warnings/Precautions:

Risk of severe myelosuppression; reduce dose or discontinue if necessary. Monitor blood counts at baseline and at least once a week during therapy. Correct severe anemia before starting. Markedly depressed bone marrow function: do not initiate. Monitor for malignancies. Avoid sun exposure. Previous irradiation therapy (monitor for skin erythema) or chemotherapy. Macrocytosis may mask folic acid deficiency; prophylactic folic acid is recommended. Pulmonary toxicity. Myeloproliferative disorders; discontinue if cutaneous vasculitic ulcerations occur. Renal or hepatic impairment. Elderly. Embryo-fetal toxicity. Pregnancy; avoid. Exclude pregnancy prior to initiating; use effective contraception during and for ≥6 months (females) or ≥1 year (males) after therapy. Nursing mothers: not recommended.

Pharmacologic Class:

Antimetabolite.

Interactions:

Avoid concomitant didanosine, with or without stavudine, or other antiretrovirals (may cause pancreatitis [monitor], fatal hepatotoxicity, peripheral neuropathy). Avoid live vaccines. Increased risk of vasculitic toxicities with interferon therapy. May cause falsely elevated results in urea, uric acid, and lactic acid assays.

Adverse Reactions:

Leukopenia, thrombocytopenia, anemia, GI upset, anorexia; secondary malignancies, macrocytosis, interstitial lung disease.

Note:

Wear disposable gloves when handling caps or bottle.

How Supplied:

Caps—100

Pricing for HYDREA

500mg capsule (Qty: 60)
Appx. price $28
GoodRx